Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jun;41(6):1231–1236. doi: 10.1128/aac.41.6.1231

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.

P G Hoggard 1, S Kewn 1, M G Barry 1, S H Khoo 1, D J Back 1
PMCID: PMC163892  PMID: 9174176

Abstract

Drugs commonly administered to patients infected with the human immunodeficiency virus (HIV) have been studied for their propensity to alter the intracellular phosphorylation of the anti-HIV nucleoside analog stavudine (2',3'-dideoxy-2',3'-didehydrothymidine; d4T) in peripheral blood mononuclear cells (PBMCs) and U937 cells in vitro. PBMCs isolated from the blood of healthy volunteers were stimulated by the mitogen phytohemagglutinin (10 microg/ml) for 72 h. Stimulated PBMCs (3 x 10(6) cells/plate) were then incubated with [3H]d4T (0.65 microCi; 3 microM) and either acyclovir, dapsone, ddC, ddI, fluconazole, foscarnet, ganciclovir, itraconazole, lobucavir, ranitidine, ribavirin, rifampin, sorivudine, sulfamethoxazole, trimethoprim, lamivudine (3TC), zidovudine, or thymidine (30 and 300 microM) for 24 h. Doxorubicin and drugs showing some evidence of inhibition were also studied at 0.3 and 3 microM. Cells were extracted overnight with 60% methanol prior to analysis by radiometric high-performance liquid chromatography. Additional data for nine of the drugs were obtained by incubation with [3H]d4T in U937 cells for 24 h. The effect of d4T (0.2 to 20 microM) on zidovudine (0.65 microCi; 0.018 microCi) phosphorylation was also studied. Zidovudine significantly reduced d4T total phosphates in PBMCs and U937 cells (in PBMCs to 33% [P < 0.001] and 17% [P < 0.001] of that in control cells at 3 and 30 microM, respectively). A small reduction in zidovudine phosphorylation was seen with d4T but only at d4T:zidovudine ratios of 100 and 1,000. Of the other compounds screened, only thymidine, ribavirin, and doxorubicin produced inhibition of d4T phosphorylation in both PBMCs and U937 cells. However, doxorubicin was cytotoxic at 3 microM. The decrease in d4T phosphorylation in the presence of ribavirin is consistent with previous findings with zidovudine. Although ddC significantly inhibited the phosphorylation of d4T in PBMCs, this was not seen in U937 cells, and it is probable that the findings in PBMCs are related to mitochondrial toxicity [based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide cytotoxicity assay]. The only drugs screened which may interfere with d4T phosphorylation at clinically relevant concentrations were zidovudine, ribavirin, and doxorubicin.

Full Text

The Full Text of this article is available as a PDF (210.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia G., Cooney D. A., Mitsuya H., Fridland A., Flora K. P., Hao Z., Dalal M., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol. 1987 Nov 15;36(22):3797–3800. doi: 10.1016/0006-2952(87)90440-0. [DOI] [PubMed] [Google Scholar]
  2. Aronoff G. R., Bergstrom R. F., Pottratz S. T., Sloan R. S., Wolen R. L., Lemberger L. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984 Jul;36(1):138–144. doi: 10.1038/clpt.1984.152. [DOI] [PubMed] [Google Scholar]
  3. Baba M., Pauwels R., Balzarini J., Herdewijn P., De Clercq E., Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 1987 Oct;31(10):1613–1617. doi: 10.1128/aac.31.10.1613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baba M., Pauwels R., Herdewijn P., De Clercq E., Desmyter J., Vandeputte M. Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun. 1987 Jan 15;142(1):128–134. doi: 10.1016/0006-291x(87)90460-8. [DOI] [PubMed] [Google Scholar]
  5. Balzarini J., Herdewijn P., De Clercq E. Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem. 1989 Apr 15;264(11):6127–6133. [PubMed] [Google Scholar]
  6. Balzarini J., Kang G. J., Dalal M., Herdewijn P., De Clercq E., Broder S., Johns D. G. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides. Mol Pharmacol. 1987 Jul;32(1):162–167. [PubMed] [Google Scholar]
  7. Barry M. G., Khoo S. H., Veal G. J., Hoggard P. G., Gibbons S. E., Wilkins E. G., Williams O., Breckenridge A. M., Back D. J. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS. 1996 Oct;10(12):1361–1367. doi: 10.1097/00002030-199610000-00008. [DOI] [PubMed] [Google Scholar]
  8. Blakley R. L., Harwood F. C., Huff K. D. Cytostatic effects of 2',3'-dideoxyribonucleosides on transformed human hemopoietic cell lines. Mol Pharmacol. 1990 Feb;37(2):328–332. [PubMed] [Google Scholar]
  9. Browne M. J., Mayer K. H., Chafee S. B., Dudley M. N., Posner M. R., Steinberg S. M., Graham K. K., Geletko S. M., Zinner S. H., Denman S. L. 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993 Jan;167(1):21–29. doi: 10.1093/infdis/167.1.21. [DOI] [PubMed] [Google Scholar]
  10. Burger D. M., Meenhorst P. L., Koks C. H., Beijnen J. H. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother. 1993 Jul;37(7):1426–1431. doi: 10.1128/aac.37.7.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cammack N., Rouse P., Marr C. L., Reid P. J., Boehme R. E., Coates J. A., Penn C. R., Cameron J. M. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. Biochem Pharmacol. 1992 May 28;43(10):2059–2064. doi: 10.1016/0006-2952(92)90162-c. [DOI] [PubMed] [Google Scholar]
  12. Chen C. H., Cheng Y. C. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine. J Biol Chem. 1992 Feb 15;267(5):2856–2859. [PubMed] [Google Scholar]
  13. Eksborg S., Ehrsson H., Andersson I. Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. J Chromatogr. 1979 Dec 1;164(4):479–486. doi: 10.1016/s0378-4347(00)81550-9. [DOI] [PubMed] [Google Scholar]
  14. Hansen M. B., Nielsen S. E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989 May 12;119(2):203–210. doi: 10.1016/0022-1759(89)90397-9. [DOI] [PubMed] [Google Scholar]
  15. Ho H. T., Hitchcock M. J. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother. 1989 Jun;33(6):844–849. doi: 10.1128/aac.33.6.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hoggard P. G., Veal G. J., Wild M. J., Barry M. G., Back D. J. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother. 1995 Jun;39(6):1376–1378. doi: 10.1128/aac.39.6.1376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Klecker R. W., Jr, Collins J. M., Yarchoan R. C., Thomas R., McAtee N., Broder S., Myers C. E. Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol. 1988 Sep;28(9):837–842. doi: 10.1002/j.1552-4604.1988.tb03225.x. [DOI] [PubMed] [Google Scholar]
  18. Kremers P., Duvivier J., Heusghem C. Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses. J Clin Pharmacol. 1974 Feb-Mar;14(2):112–117. doi: 10.1002/j.1552-4604.1974.tb02300.x. [DOI] [PubMed] [Google Scholar]
  19. Laskin O. L., Longstreth J. A., Hart C. C., Scavuzzo D., Kalman C. M., Connor J. D., Roberts R. B. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1987 May;41(5):546–555. doi: 10.1038/clpt.1987.70. [DOI] [PubMed] [Google Scholar]
  20. Mansuri M. M., Starrett J. E., Jr, Ghazzouli I., Hitchcock M. J., Sterzycki R. Z., Brankovan V., Lin T. S., August E. M., Prusoff W. H., Sommadossi J. P. 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J Med Chem. 1989 Feb;32(2):461–466. doi: 10.1021/jm00122a029. [DOI] [PubMed] [Google Scholar]
  21. Merrill D. P., Moonis M., Chou T. C., Hirsch M. S. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996 Feb;173(2):355–364. doi: 10.1093/infdis/173.2.355. [DOI] [PubMed] [Google Scholar]
  22. Murray H. W., Squires K. E., Weiss W., Sledz S., Sacks H. S., Hassett J., Cross A., Anderson R. E., Dunkle L. M. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis. 1995 Mar;171 (Suppl 2):S123–S130. doi: 10.1093/infdis/171.supplement_2.s123. [DOI] [PubMed] [Google Scholar]
  23. Sommadossi J. P., Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother. 1987 Mar;31(3):452–454. doi: 10.1128/aac.31.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sommadossi J. P. Nucleoside analogs: similarities and differences. Clin Infect Dis. 1993 Feb;16 (Suppl 1):S7–15. doi: 10.1093/clinids/16.supplement_1.s7. [DOI] [PubMed] [Google Scholar]
  25. Taburet A. M., Katlama C., Blanshard C., Zorza G., Gazzard D., Dohin E., Gazzard B. G., Frostegard C., Singlas E. Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients. Antimicrob Agents Chemother. 1992 Sep;36(9):1821–1824. doi: 10.1128/aac.36.9.1821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Veal G. J., Hoggard P. G., Barry M. G., Khoo S., Back D. J. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS. 1996 May;10(5):546–548. doi: 10.1097/00002030-199605000-00016. [DOI] [PubMed] [Google Scholar]
  27. Veal G. J., Wild M. J., Barry M. G., Back D. J. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Br J Clin Pharmacol. 1994 Oct;38(4):323–328. doi: 10.1111/j.1365-2125.1994.tb04361.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Vogt M. W., Hartshorn K. L., Furman P. A., Chou T. C., Fyfe J. A., Coleman L. A., Crumpacker C., Schooley R. T., Hirsch M. S. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science. 1987 Mar 13;235(4794):1376–1379. doi: 10.1126/science.2435003. [DOI] [PubMed] [Google Scholar]
  29. Zhu Z., Hitchcock M. J., Sommadossi J. P. Metabolism and DNA interaction of 2',3'-didehydro-2',3'-dideoxythymidine in human bone marrow cells. Mol Pharmacol. 1991 Nov;40(5):838–845. [PubMed] [Google Scholar]
  30. Zhu Z., Ho H. T., Hitchcock M. J., Sommadossi J. P. Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. Biochem Pharmacol. 1990 May 1;39(9):R15–R19. doi: 10.1016/0006-2952(90)90418-k. [DOI] [PubMed] [Google Scholar]
  31. van Leeuwen R., Katlama C., Kitchen V., Boucher C. A., Tubiana R., McBride M., Ingrand D., Weber J., Hill A., McDade H. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995 May;171(5):1166–1171. doi: 10.1093/infdis/171.5.1166. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES